Favorable News Coverage Extremely Likely to Affect Taro Pharmaceutical Industries (TARO) Stock Price

News coverage about Taro Pharmaceutical Industries (NYSE:TARO) has been trending positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Taro Pharmaceutical Industries earned a daily sentiment score of 0.26 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 100 out of 100, meaning that recent news coverage is extremely likely to have an effect on the company’s share price in the next several days.

Here are some of the news articles that may have effected Accern’s rankings:

Insider Buying and Selling by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

TARO has been the subject of a number of recent analyst reports. TheStreet upgraded shares of Taro Pharmaceutical Industries from a “c+” rating to a “b” rating in a research note on Wednesday, April 12th. BidaskClub lowered shares of Taro Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research report on Friday, June 9th. Finally, Credit Suisse Group lowered shares of Taro Pharmaceutical Industries from an “outperform” rating to a “neutral” rating in a research report on Tuesday, May 23rd.

Shares of Taro Pharmaceutical Industries (NYSE TARO) traded up 0.14% during midday trading on Tuesday, reaching $112.16. 55,461 shares of the company traded hands. Taro Pharmaceutical Industries has a 1-year low of $92.28 and a 1-year high of $148.00. The stock’s 50-day moving average is $110.70 and its 200-day moving average is $110.78. The stock has a market capitalization of $4.55 billion, a P/E ratio of 10.15 and a beta of 0.63.

Taro Pharmaceutical Industries (NYSE:TARO) last released its quarterly earnings data on Monday, May 22nd. The company reported $2.05 earnings per share (EPS) for the quarter. Taro Pharmaceutical Industries had a return on equity of 23.08% and a net margin of 51.90%. The business had revenue of $196.41 million during the quarter. Equities analysts predict that Taro Pharmaceutical Industries will post $11.00 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Favorable News Coverage Extremely Likely to Affect Taro Pharmaceutical Industries (TARO) Stock Price” was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://sportsperspectives.com/2017/06/20/positive-media-coverage-extremely-likely-to-impact-taro-pharmaceutical-industries-taro-share-price-updated-updated-updated-updated.html.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply